-
Pfizer's Promising Future: Exploring Analyst Insights and Stock Forecasts for 2025
- 2025/01/11
- 再生時間： 2 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Pfizer's stock, trading under the symbol PFE, has been a subject of interest for investors and analysts alike. As of January 11, 2025, the most recent closing stock price for Pfizer is 26.86 dollars[1].
In terms of trading volume, specific data on the current trading volume versus the average is not provided in the available sources. However, historical data indicates that Pfizer's stock has experienced fluctuations in trading volume, which can be influenced by various market and company-specific factors.
Recent news and announcements about Pfizer include the company's ongoing efforts in the pharmaceutical industry, particularly in developing new treatments and vaccines. However, specific recent news or announcements are not detailed in the provided sources.
Major analyst updates and price target changes include a consensus price target of 32 dollars, representing an 18.87% upside from the current price, according to 16 analysts[2]. Another source indicates a consensus price target of 37.09 dollars based on the ratings of 24 analysts, with the high being 60 dollars issued by Goldman Sachs and the low being 25 dollars issued by Wolfe Research[3].
Other relevant information includes forecasts from various sources. WalletInvestor predicts a slight decline in Pfizer stock in 2025, with a forecast ranging from 23.837 to 28.105 dollars[4]. In contrast, PandaForecast anticipates sustained growth throughout 2025, with prices potentially reaching 40.15 dollars by December[4]. LongForecast provides a detailed monthly forecast for 2025, indicating a steady increase in the stock price, starting from 26.53 dollars in January and reaching 38.79 dollars by December[5].
Overall, Pfizer's stock forecast is cautiously optimistic, with analysts anticipating potential growth driven by the company's strong product lineup and promising new treatments and vaccines. However, investors should note the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories.
In terms of trading volume, specific data on the current trading volume versus the average is not provided in the available sources. However, historical data indicates that Pfizer's stock has experienced fluctuations in trading volume, which can be influenced by various market and company-specific factors.
Recent news and announcements about Pfizer include the company's ongoing efforts in the pharmaceutical industry, particularly in developing new treatments and vaccines. However, specific recent news or announcements are not detailed in the provided sources.
Major analyst updates and price target changes include a consensus price target of 32 dollars, representing an 18.87% upside from the current price, according to 16 analysts[2]. Another source indicates a consensus price target of 37.09 dollars based on the ratings of 24 analysts, with the high being 60 dollars issued by Goldman Sachs and the low being 25 dollars issued by Wolfe Research[3].
Other relevant information includes forecasts from various sources. WalletInvestor predicts a slight decline in Pfizer stock in 2025, with a forecast ranging from 23.837 to 28.105 dollars[4]. In contrast, PandaForecast anticipates sustained growth throughout 2025, with prices potentially reaching 40.15 dollars by December[4]. LongForecast provides a detailed monthly forecast for 2025, indicating a steady increase in the stock price, starting from 26.53 dollars in January and reaching 38.79 dollars by December[5].
Overall, Pfizer's stock forecast is cautiously optimistic, with analysts anticipating potential growth driven by the company's strong product lineup and promising new treatments and vaccines. However, investors should note the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories.